Clinical Trial Update: Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 SONIA trial evaluating endocrine therapy plus a CDK4/6 inhibitor as first- or second-line treatment for hormone receptor-positive advanced breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor (unspecified)

Snippet

Sponsor: Borstkanker Onderzoek Groep | Conditions: Breast Neoplasm Female | Phase 3 | Status: ACTIVE_NOT_RECRUITING